SCHEMBL3361201

SCHEMBL3361201

O=c1nccc(-c2ccccc2)[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.53
ALDH1A1 P00352 1/20 0.53
HPGD P15428 1/20 0.53
HSD17B10 Q99714 1/20 0.53
NOTUM Q6P988 1/20 0.52
POLB P06746 1/20 0.52
CDC7 O00311 2/20 0.50
SCN4A P35499 1/20 0.48
MAPT P10636 2/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
GLA P06280 1/20 0.47
KMT2A Q03164 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
GAA P10253 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
ADORA2A P29274 1/20 0.46
ADORA1 P30542 1/20 0.46
TAS2R38 P59533 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL916879 0.76 POLB (0.44) ALDH1A1HPGDNOTUMPOLBNPC1
SCHEMBL20510086 0.75 KDM4E (0.50) KDM4EALDH1A1HPGDHSD17B10POLB
SCHEMBL30205335 0.75 MAP2K1 (0.57) KDM4EALDH1A1HPGDSCN4AMAPT
SCHEMBL13977309 0.71 CDC7 (0.57) KDM4ECDC7MAPTNPC1RAB9A
SCHEMBL6196932 0.71 NOTUM (0.56) ALDH1A1HPGDNOTUMMAPTNPY5R
SCHEMBL1536003 0.70 NOTUM (0.56) KDM4EALDH1A1HPGDHSD17B10NOTUM
SCHEMBL6508629 0.70 HPGD (0.49) KDM4EALDH1A1HPGDHSD17B10CDC7
Biphenyl SCHEMBL21523336 0.70 SCN4A (0.54) KDM4EALDH1A1HPGDNOTUMPOLB
SCHEMBL28544732 0.69 KDM4E (1.00) KDM4EALDH1A1HPGDHSD17B10POLB
SCHEMBL15335986 0.69 KDM4E (0.51) KDM4EALDH1A1HPGDHSD17B10CDC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115710251-A Myeloid differentiation factor 88 inhibitor and preparation method and application thereof 杭州医学院 2023-02-24 CN claimed
WO-2026017114-A1 USE OF PHENYLPYRIMIDINONE COMPOUND 苏州旺山旺水生物医药股份有限公司 2026-01-22 WO disclosed
CN-115710251-B Medullary differentiation factor 88 inhibitor and preparation method and application thereof 杭州医学院 2024-05-28 CN disclosed
CN-117157285-A Pharmaceutical compounds as ubiquitin-specific protease 19 (USP 19) inhibitors 阿尔麦克探索有限公司 2023-12-01 CN disclosed
CN-115710251-A Myeloid differentiation factor 88 inhibitor and preparation method and application thereof 杭州医学院 2023-02-24 CN disclosed
US-8242129-B2 6-phenylpyrimidinones as PIM modulators EXELIXIS, INC. (US) 2012-08-14 US disclosed
CN-102317266-A 6-phenylpyrimidinones as PIM modulators EXELIXIS INC 2012-01-11 CN disclosed
US-20100135954-A1 6-Phenylpyrimidinones as PIM Modulators EXELIXIS, INC. (US) 2010-06-03 US disclosed
EP-0863882-B1 AMINO SUBSTITUTED PYRIMIDINES AND TRIAZINES JANSSEN PHARMACEUTICA NV (BE) 2002-02-06 EP disclosed
US-6288060-B1 CORTICOTROPIN RELEASING FACTOR ANTAGONISTS; ANXIOLYTIC, ANTIDEPRESSANT, ANTIINFLAMMATORY AGENTS; EATING DISORDERS NEUROCRINE BIOSCIENCES, INC. 2001-09-11 US disclosed
EP-0863882-A1 AMINO SUBSTITUTED PYRIMIDINES AND TRIAZINES JANSSEN PHARMACEUTICA N.V. (BE) 1998-09-16 EP disclosed
WO-1997014684-A1 AMINO SUBSTITUTED PYRIMIDINES AND TRIAZINES JANSSEN PHARMACEUTICA N.V. (BE) 1997-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100135954-A1 6-Phenylpyrimidinones as PIM Modulators PIM1, PIM2, PIM3 KDM4E 672/4885ALDH1A1 851/4885HPGD 2939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.